Insider Transactions and Investment DecisionMaking

On November 21, 2023, Michael O'Sullivan, the General Counsel at Snap, made a significant insider transaction by selling 35,683 shares ...

Snap and Amazon Partner to Enable InApp Shopping on Snapchat

by Elaine Mendonça

November 15, 2023

Snap shares are experiencing a notable uptick in trading activity as reports surface about an intriguing partnership between the social ...

Adams Diversified Equity Announces Quarterly Dividend and ExDividend Date

by Yasmim Mendonça

November 15, 2023

On November 15, 2023, Adams Diversified Equity (NYSE: ADX) made an important announcement regarding their dividend. Understanding the ex-dividend date ...

Snap Unveils Lens Studio 50 Beta Revolutionizing AR Development with AI Integration and Enhanced Productivity

by Yasmim Mendonça

November 9, 2023

Snap, the popular social media platform, is set to unveil its latest innovation in augmented reality (AR) development. Lens Studio ...

Earnings Preview For G1 TherapeuticsG1 Therapeutics (NASDAQ:GTHX) is set to give its latest quarterly earnings report on Wednesday, 2023-11-01. Here's what investors need to know before the announcement. Analysts estimate that G1 Therapeutics will report an earnings per share (EPS) of $-0.33. G1 Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.31, which was followed by a 4.67% increase in the share price the next day. Here's a look at G1 Therapeutics's past performance and the resulting price change: Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022 EPS Estimate -0.17 -0.64 -0.84 -0.63 EPS Actual 0.14 -0.53 -0.73 -0.59 Price Change % 4.67% 3.97% -0.82% -3.41% Stock Performance Shares of G1 Therapeutics were trading at $1.58 as of October 30. Over the last 52-week period, shares are down 79.9%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. To track all earnings releases for G1 Therapeutics visit their earnings calendar on our site. Market trends market news

Options Trading and Price Targets for Snap

by Elaine Mendonça

November 3, 2023

As of November 3, 2023, an affluent investor who possesses significant financial resources has taken a notable bearish position on ...

Aerospace and Defense Market Capitalization

Snaps Earnings Report and Stock Performance An Evaluation and Outlook

by Elaine Mendonça

October 23, 2023

Snap (NYSE: SNAP) is scheduled to release its latest quarterly earnings report on Tuesday, October 24, 2023. Analysts predict that ...

Jordans Foreign Minister Urges Immediate Action and Humanitarian Aid in Gaza Crisis

by Yasmim Mendonça

October 19, 2023

On October 19, 2023, Jordan's Foreign Minister, Ayman Safadi, voiced his deep apprehension regarding the ongoing conflict in Gaza. With ...

Notable Options Activity and Market Analysis for Snap on October 18 2023

by Yasmim Mendonça

October 19, 2023

October 18, 2023 A remarkable development has emerged in the options history of Snap, indicating a significant player with substantial ...

Snap Inc Sets Ambitious Goals for Growth and Expansion

by Yasmim Mendonça

October 16, 2023

Snap Inc. has set ambitious internal goals for the year 2024, aiming to achieve significant growth and expansion. The company ...

Snaps Ambitious Goals and Positive Impact on Stock Price

by Elaine Mendonça

October 16, 2023

Snap shares are experiencing a surge in trading following an intriguing report from The Verge regarding the company's internal objectives ...

Tag: snap